Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Date:8/11/2011
THE WOODLANDS, Texas, Aug. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Wedbush 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011 at 1:15 p.m. Eastern Time in New York City. Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.
A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com. An archived version of the webcast will be available for 30 days after the event on the company's website.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intell
'/>"/>
| SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
2. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
4. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
8. Lexicon to Provide First Quarter 2011 Financial Results
9. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
10. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
(Date:6/18/2013)... 2013 , Safinamide significantly ... patients as add-on to levodopa Safinamide ... symptoms in fluctuating PD patients as add-on to ... S.p.A. ("Newron"), a research and development company focused ... partner Zambon S.p.A., a pharmaceutical company strongly committed ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... public offering of common shares (the "Offering"). Pursuant to ... at a price of $85.00 per share, for aggregate ... file a final prospectus supplement to its effective shelf ... similar filing with the securities regulatory authorities in each ...
(Date:6/18/2013)... , June 18, 2013 It has ... of Alliance Seating and Mobility, a subsidiary company ... access timely repair. This appears to be due ... reduction of field service employees. ... great many of these clients are complex mobility ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4... 2011 NeoStem, Inc. (NYSE Amex: NBS ... with operations in the U.S. and China, today announced ... has been recommended for funding by the Department of ... the Office of the Congressionally Directed Medical Research Programs ...
... Reportlinker.com announces that a new market research report ... S.A.: PharmaVitae Profile http://www.reportlinker.com/p0177525/UCB-SA-PharmaVitae-Profile.html ... analysis examines the historical and forecast performance for UCB ... company strategy, portfolio and pipeline analysis and assessment of ...
Cached Medicine Technology:$1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program 2$1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program 3$1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program 4Reportlinker Adds UCB S.A.: PharmaVitae Profile 2(Date:6/19/2013)... (PRWEB) June 19, 2013 Blueforce ... and sensor machine software, today announced it has ... its Decentralized Fusion Engine technology. The award ... the acquisition of key strategic partnerships. , ... wireless collaboration and machine-to-machine (M2M) software products that ...
(Date:6/19/2013)... A blow to the head; a swift jarring to ... to hours. It’s understandable, but what else may follow ... traumatic brain injury. According to mayoclinic.com , usual ... But many other symptoms may follow, sometimes not for ... include ongoing headaches, dizziness, feeling like you’re in a fog, ...
(Date:6/19/2013)... 19, 2013 Walkingspree, a specialized wellness ... the launch of its new Facebook App. This is ... inspire participants to reach their program fitness goals. Consistent ... Walkingspree clients are given more tools to customize their ... , Corporate clients may choose whether or not they ...
(Date:6/19/2013)... Weight gain and obesity have been ... including heart disease, kidney failure and high blood pressure. ... and unnecessary fat, have many people searching for fast ... diets to not only allow patients to succeed ... aim to reduce the risk for many weight-related health ...
(Date:6/19/2013)... June 19, 2013 The reason for the ... because users can place a 4x8 flood tray inside the ... to work around. In addition, Gorilla Grow Tents are ... are the tallest, thickest and strongest grow tents on the ... grow tent standards. , Gorilla Grow Tents are ...
Breaking Medicine News(10 mins):Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Stealth Grow Tent Brand’s Popularity Rises 2[0] Blueforce Awarded Patent for Decentralized Sensor Fusion[0] Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist[0] Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement[0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns[0] Stealth Grow Tent Brand’s Popularity Rises
... disused proteins are eliminated by a cellular shredder called ... to dispose with Ubiquitin (Ub) in order to avoid ... in the ubiquitin-proteasome system can be fatal for the ... disorders but also developmental defects are the consequences. The ...
... the first scientific review of a dozen patients who have ... gene therapy technique is safe and may be effective at ... patients, half of whom live on Long Island, are in ... to medicines when they signed on for the experimental therapy. ...
... on June 26, after spending 23 days in the slammer. ... Angeles County Sheriff's Department's Inmate Reception Center. ,The exact ... ,Although her sentence was for 45 days, authorities have said ... good behaviour. ,"There was some confusion as to whether ...
... new details about how proteins used to destroy bacteria ... ,Gunnar K. Gouras, associate professor of neurology and ... York, and colleagues provide new insights into how these ... disease and raise hopes for a vaccine against the ...
... a credible scientific method for testing and measuring ... on XanGo Juice , indicate usage of the ... to high xanthone absorption. ,XanGo, LLC, ... leading scientific exploration of the whole mangosteen fruit ...
... is making all possible arrangements to look good on her yet ... thing that the socialite will do after being released on June ... complained to the press while in jail that she's not permitted ... going dry. ,So, the heiress has booked a facial ...
Cached Medicine News:Health News:Protein Targets for Carcinogenesis 2Health News:Gene Therapy for Parkinsons Disease 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 3Health News:New Technique to Measure Xanthone in Mangosteen 2Health News:New Technique to Measure Xanthone in Mangosteen 3Blunt Weitlaner Retractor....
Weitlaner Beckmann retractor, sharp prongs, SS....
Baby Weitlaner retractor, blunt, 4"....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |